PERTH, Australia - Melbourne-headquartered ChemGenex will see its first product Omapro under review by U.S. FDA's Oncologic Drugs Advisory Committee Feb. 10 for patients with chronic myeloid leukemia who have failed to respond to Gleevec and who have the Bcr-Abl T315I mutation
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
